Tempus AI, Inc. (TEM) - Stock Analysis
Last updated: Jan 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Negative free cashflow ⢠Elevated leverage TEM combines strong gross margins and solid short-term liquidity with persistent operating losses, negative free cash flow, heavy leverage, and rich valuation multiples, indicating reliance on external financing and limited financial flexibility.
Price Behavior
Key Price Behavior Insights: ⢠Downward momentum ⢠Support breach ⢠Resistance clamp Support Level: $64 Resistance Level: $70â$71 TEM has traded lower over the last month, sliding from near $77 to about $67, breaking repeated tests of $64 support and failing to sustain rallies above $70â$71, signaling developing bearish momentum but scope for a rebound if $70 is reclaimed.
Sentiment & News
Key News Insights: ⢠Strong revenue ⢠Margin gains ⢠Large partnerships Tempus AI showed rapid revenue and diagnostics growth, improving margins and adjusted EBITDA progress backed by large partnerships and bookings, but GAAP losses, revenue-recognition delays and diagnostic competition keep near-term risks.
AI Summary
TEM has shifted from a speculative AI/R&D story into a scaling diagnostics and data platform with improving gross margins and positive adjusted EBITDA episodes, making sustained adjusted EBITDA-to-free-cash-flow conversion the primary value driver rather than pure topâline growth. The key actionable risk is reimbursement and pricing cadence for MRD and core testsâtrack payer decisions, PMA milestones, and quarterly cash generation closely, as misses would quickly reprice the high valuation.
Description
Tempus AI, Inc. is a healthcare technology company that performs molecular diagnostics, including next-generation sequencing, PCR profiling, genotyping and anatomic pathology for healthcare providers, pharmaceutical and biotechnology firms, and researchers. It also licenses a de-identified, linked clinicalâmolecularâimaging dataset and offers analytics, cloud compute tools, clinical trial matching, algorithmic oncology tests and software for test ordering and research workflows. The company entered strategic collaborations with AstraZeneca and Pathos AI, was incorporated in 2015, changed its name from Tempus Labs in January 2023, and is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 9 | Dec 16 | TEM | Tempus AI, Inc. | Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential. | Closed | -10.2% |